{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:32:14Z","timestamp":1791822734756,"version":"4.3.4"},"reference-count":83,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1614,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>\n                                 <jats:bold>Recent progress in understanding the molecular mechanisms of bile formation and cholestasis have led to new insights into the pathogenesis of drug-induced cholestasis. This review summarizes their variable clinical presentations, examines the role of transport proteins in hepatic drug clearance and toxicity, and addresses the increasing importance of genetic determinants, as well as practical aspects of diagnosis and management. (HEPATOLOGY 2011;)<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.24229","type":"journal-article","created":{"date-parts":[[2011,2,18]],"date-time":"2011-02-18T11:45:20Z","timestamp":1298029520000},"page":"1377-1387","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":308,"title":["Drug-induced cholestasis"],"prefix":"10.1097","volume":"53","author":[{"given":"Manmeet S.","family":"Padda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayra","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbasi J.","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-32-20241104","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMra021844","article-title":"Drug-induced hepatotoxicity.","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"R2-32-20241104","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2165\/11535340-000000000-00000","article-title":"Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work.","volume":"33","author":"Suzuki","year":"2010","journal-title":"Drug Saf"},{"key":"R3-32-20241104","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1517\/17425250902927386","article-title":"Human drug hepatotoxicity: a contemporary clinical perspective.","volume":"5","author":"Assis","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R4-32-20241104","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1002\/hep.23577","article-title":"; US Drug-Induced Liver Injury Network. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method.","volume":"51","author":"Rockey","year":"2010","journal-title":"HEPATOLOGY"},{"key":"R5-32-20241104","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1055\/s-2002-30099","article-title":"Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions.","volume":"22","author":"Bohan","year":"2002","journal-title":"Semin Liver Dis"},{"key":"R6-32-20241104","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/hep.20800","article-title":"Outcome and prognostic markers in severe drug-induced liver disease.","volume":"42","author":"Bjornsson","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R7-32-20241104","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/hep.23317","article-title":"Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events.","volume":"51","author":"Lammert","year":"2010","journal-title":"HEPATOLOGY"},{"key":"R8-32-20241104","first-page":"1232","article-title":"Drug and toxin-induced bile duct disorders.","volume":"15","author":"Geubel","year":"2000","journal-title":"J Gastroenterol Hepatol"},{"key":"R9-32-20241104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0046-8177(70)80002-8","article-title":"Pathophysiology of cholestasis.","volume":"1","author":"Popper","year":"1970","journal-title":"Hum Pathol"},{"key":"R10-32-20241104","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1001\/archinte.1979.03630460070021","article-title":"Intrahepatic cholestasis.","volume":"139","author":"Zimmerman","year":"1979","journal-title":"Arch Intern Med"},{"key":"R11-32-20241104","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2796.1992.tb00562.x","article-title":"Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987.","volume":"232","author":"Friis","year":"1992","journal-title":"J Intern Med"},{"key":"R12-32-20241104","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0025-7125(05)70287-X","article-title":"Drug-induced liver disease.","volume":"84","author":"Lewis","year":"2000","journal-title":"Med Clin North Am"},{"key":"R13-32-20241104","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.0954-6820.1967.tb10873.x","article-title":"Infective hepatitis and toxic jaundice in a municipal hospital during a five-year period: incidence and prognosis.","volume":"182","author":"BjOrneboe","year":"1967","journal-title":"Acta Med Scand"},{"key":"R14-32-20241104","first-page":"1","article-title":"Causes and characteristics of 500 consecutive causes of jaundice.","volume":"16","author":"Malchow-MOller","year":"1981","journal-title":"Scand J Gastroenterol"},{"key":"R15-32-20241104","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/gut.48.3.409","article-title":"The causes of obvious jaundice in South West Wales: perceptions versus reality.","volume":"48","author":"Whitehead","year":"2001","journal-title":"Gut"},{"key":"R16-32-20241104","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/00365520310000492","article-title":"Severe jaundice in Sweden in the new millennium: causes, investigations, treatment and prognosis.","volume":"38","author":"Bjornsson","year":"2003","journal-title":"Scand J Gastroenterol"},{"key":"R17-32-20241104","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1055\/s-2002-30102","article-title":"Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs.","volume":"22","author":"Chitturi","year":"2002","journal-title":"Semin Liver Dis"},{"key":"R18-32-20241104","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0016-5085(79)91333-7","article-title":"Erythromycin ethylsuccinate-induced cholestasis.","volume":"76","author":"Viteri","year":"1979","journal-title":"Gastroenterology"},{"key":"R19-32-20241104","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0016-5085(19)34313-6","article-title":"Biliary cirrhosis induced by chlorpromazine.","volume":"51","author":"Walker","year":"1966","journal-title":"Gastroenterology"},{"key":"R20-32-20241104","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/hep.1840200610","article-title":"Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis.","volume":"20","author":"Moradpour","year":"1994","journal-title":"HEPATOLOGY"},{"issue":"Suppl 1","key":"R21-32-20241104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-8278(97)82326-4","article-title":"Drug-induced cholestasis.","volume":"26","author":"Erlinger","year":"1997","journal-title":"J Hepatol"},{"key":"R22-32-20241104","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0168-8278(95)80262-2","article-title":"Liver injury related to amoxycillin-clavulanic acid: interlobular bile-duct lesions and extrahepatic manifestations.","volume":"22","author":"Hautekeete","year":"1995","journal-title":"J Hepatol"},{"key":"R23-32-20241104","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00005792-199309000-00001","article-title":"Toxic oil syndrome. A long-term follow-up of a cohort of 332 patients.","volume":"72","author":"Alonso-Ruiz","year":"1993","journal-title":"Medicine (Baltimore)"},{"key":"R24-32-20241104","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/hep.1840150212","article-title":"Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia.","volume":"15","author":"Degott","year":"1992","journal-title":"HEPATOLOGY"},{"key":"R25-32-20241104","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1056\/NEJM199703203361204","article-title":"Idiopathic biliary ductopenia in adults without symptoms of liver disease.","volume":"336","author":"Moreno","year":"1997","journal-title":"N Engl J Med"},{"key":"R26-32-20241104","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1089-3261(03)00028-X","article-title":"Bile duct disorders.","volume":"7","author":"Geubel","year":"2003","journal-title":"Clin Liver Dis"},{"key":"R27-32-20241104","first-page":"392","article-title":"Destructive intrahepatic bile duct diseases.","volume":"81","author":"Desmet","year":"1990","journal-title":"Recent Prog Med"},{"key":"R28-32-20241104","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJM199810223391707","article-title":"Molecular pathogenesis of cholestasis.","volume":"339","author":"Trauner","year":"1998","journal-title":"N Engl J Med"},{"key":"R29-32-20241104","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/hep.21359","article-title":"Hepatobiliary transporters and drug-induced cholestasis.","volume":"44","author":"Pauli-Magnus","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R30-32-20241104","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0889-8553(21)00228-4","article-title":"Mechanisms of drug-induced liver disease.","volume":"24","author":"DeLeve","year":"1995","journal-title":"Gastroenterol Clin North Am"},{"key":"R31-32-20241104","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S1089-3261(02)00025-9","article-title":"Immune-mediated drug-induced liver disease.","volume":"6","author":"Liu","year":"2002","journal-title":"Clin Liver Dis"},{"key":"R32-32-20241104","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3109\/03602530903492004","article-title":"Role of the bile salt export pump, BSEP, in acquired forms of cholestasis.","volume":"42","author":"Stieger","year":"2010","journal-title":"Drug Metab Rev"},{"key":"R33-32-20241104","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1067\/mcp.2001.114667","article-title":"The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions.","volume":"69","author":"Fattinger","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"R34-32-20241104","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0300-483X(01)00460-7","article-title":"Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate.","volume":"167","author":"Funk","year":"2001","journal-title":"Toxicology"},{"key":"R35-32-20241104","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1124\/mol.59.3.627","article-title":"Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat.","volume":"59","author":"Funk","year":"2001","journal-title":"Mol Pharmacol"},{"key":"R36-32-20241104","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0016-5085(00)70224-1","article-title":"Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver.","volume":"118","author":"Stieger","year":"2000","journal-title":"Gastroenterology"},{"key":"R37-32-20241104","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S0016-5085(99)70356-2","article-title":"Sulindac is excreted into bile by a canalicular bile salt pump and undergoes a cholehepatic circulation in rats.","volume":"117","author":"Bolder","year":"1999","journal-title":"Gastroenterology"},{"key":"R38-32-20241104","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0014-5793(93)80403-H","article-title":"Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane.","volume":"333","author":"Bohme","year":"1993","journal-title":"FEBS Lett"},{"key":"R39-32-20241104","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/0016-5085(93)90363-H","article-title":"Inhibition by cyclosporin A of adenosine triphosphate-dependent transport from the hepatocyte into bile.","volume":"104","author":"Kadmon","year":"1993","journal-title":"Gastroenterology"},{"key":"R40-32-20241104","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0016-5085(94)90084-1","article-title":"Cholestasis caused by inhibition of the adenosine triphosphate-dependent bile salt transport in rat liver.","volume":"107","author":"Bohme","year":"1994","journal-title":"Gastroenterology"},{"key":"R41-32-20241104","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/hep.1840120114","article-title":"Inhibition of hepatocytary vesicular transport by cyclosporin A in the rat: relationship with cholestasis and hyperbilirubinemia.","volume":"12","author":"Roman","year":"1990","journal-title":"HEPATOLOGY"},{"key":"R42-32-20241104","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/0006-2952(94)90352-2","article-title":"Disruption of canalicular function in isolated rat hepatocyte couplets caused by cyclosporin A.","volume":"48","author":"Roman","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"R43-32-20241104","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/toxsci\/71.2.276","article-title":"Cyclosporin A induced internalization of the bile salt export pump in isolated rat hepatocyte couplets.","volume":"71","author":"Roman","year":"2003","journal-title":"Toxicol Sci"},{"key":"R44-32-20241104","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1042\/bj3540591","article-title":"Cyclosporin A reduces canalicular membrane fluidity and regulates transporter function in rats.","volume":"354","author":"Yasumiba","year":"2001","journal-title":"Biochem J"},{"key":"R45-32-20241104","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1600-0773.2001.890304.x","article-title":"Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver following treatment with cyclosporine A and sirolimus (Rapamycin).","volume":"89","author":"Bramow","year":"2001","journal-title":"Pharmacol Toxicol"},{"key":"R46-32-20241104","first-page":"1561","article-title":"The effect of troglitazone biliary excretion on metabolite distribution and cholestasis in transporter-deficient rats.","volume":"29","author":"Kostrubsky","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"R47-32-20241104","first-page":"192","article-title":"Histopathologic changes associated with fialuridine hepatotoxicity.","volume":"10","author":"Kleiner","year":"1997","journal-title":"Mod Pathol"},{"key":"R48-32-20241104","first-page":"1237","article-title":"Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis.","volume":"145","author":"Mauad","year":"1994","journal-title":"Am J Pathol"},{"key":"RU49-32-20241104","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/01.fpc.0000230418.28091.76","article-title":"Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury.","volume":"17","author":"Lang","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"R50-32-20241104","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1124\/dmd.105.008748","article-title":"Inhibition of bile acid transport across Nataurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs.","volume":"34","author":"Mita","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"R51-32-20241104","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/BF01540169","article-title":"Liver injury from cyclosporine A.","volume":"35","author":"Kassianides","year":"1990","journal-title":"Dig Dis Sci"},{"key":"R52-32-20241104","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0300-483X(01)00459-0","article-title":"Role of MRP2 and GSH in intrahepatic cycling of toxins.","volume":"167","author":"Dietrich","year":"2001","journal-title":"Toxicology"},{"key":"R53-32-20241104","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0168-8278(05)80476-3","article-title":"Antibiotic-associated acute vanishing bile duct syndrome: a pattern associated with severe, prolonged, intrahepatic cholestasis.","volume":"20","author":"Davies","year":"1994","journal-title":"J Hepatol"},{"key":"R54-32-20241104","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cld.2007.11.007","article-title":"Vanishing bile duct syndrome.","volume":"12","author":"Reau","year":"2008","journal-title":"Clin Liver Dis"},{"key":"R55-32-20241104","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S0168-8278(02)00268-4","article-title":"Delayed and prolonged cholestatic hepatitis with ductopenia after long-term ciprofloxacin therapy for Crohns disease.","volume":"37","author":"Bataille","year":"2002","journal-title":"J Hepatol"},{"key":"R56-32-20241104","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.3748\/wjg.14.4697","article-title":"Vanishing bile duct and Stevens-Johnson syndrome associated with ciprofloxacin treated with tacrolimus.","volume":"14","author":"Okan","year":"2008","journal-title":"World J Gastroenterol"},{"key":"R57-32-20241104","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1517\/14740338.2.3.287","article-title":"Drug-induced cholestasis.","volume":"2","author":"Velayudham","year":"2003","journal-title":"Expert Opin Drug Saf"},{"key":"R58-32-20241104","first-page":"80","article-title":"A case of vanishing bile duct syndrome associated with hypersensitivity to allopurinol.","volume":"11","author":"Choi","year":"2005","journal-title":"in Korean Korean J Hepatol"},{"key":"R59-32-20241104","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s10620-005-2876-2","article-title":"Vanishing bile duct syndrome and inflammatory pseudotumor associated with a case of anabolic steroid abuse.","volume":"50","author":"Capra","year":"2005","journal-title":"Dig Dis Sci"},{"key":"R60-32-20241104","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0016-5085(98)70154-4","article-title":"Drug-associated acute-onset vanishing bile duct and Stevens-Johnson syndromes in a child.","volume":"115","author":"Srivastava","year":"1998","journal-title":"Gastroenterology"},{"key":"R61-32-20241104","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jpeds.2004.05.027","article-title":"Acute vanishing bile duct syndrome after ibuprofen therapy in a child.","volume":"145","author":"Taghian","year":"2004","journal-title":"J Pediatr"},{"key":"R62-32-20241104","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0016-5085(99)70404-X","article-title":"HLA association of amoxicillin-clavulanateinduced hepatitis.","volume":"117","author":"Hautekeete","year":"1999","journal-title":"Gastroenterology"},{"key":"R63-32-20241104","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1517\/17425250903304056","article-title":"Regulation of human hepatic drug transporter expression by pro-inflammatory cytokines.","volume":"5","author":"Fardel","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R64-32-20241104","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1172\/JCI1680","article-title":"Endotoxin downregulates rat hepatic ntcp gene expression via decreased activity of critical transcription factors.","volume":"101","author":"Trauner","year":"1998","journal-title":"J Clin Invest"},{"key":"R65-32-20241104","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0300-483X(02)00255-X","article-title":"The danger hypothesispotential role in idiosyncratic drug reactions.","volume":"181-","author":"Pirmohamed","year":"2002","journal-title":"Toxicology"},{"key":"R66-32-20241104","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/toxsci\/kfn038","article-title":"Characterization of organic anion transporting polypeptide 1b2-null mice: essential role in hepatic uptaketoxicity of phalloidin and microcystin-LR.","volume":"103","author":"Lu","year":"2008","journal-title":"Toxicol Sci"},{"key":"R67-32-20241104","doi-asserted-by":"crossref","first-page":"35669","DOI":"10.1074\/jbc.M103792200","article-title":"Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans.","volume":"276","author":"Tirona","year":"2001","journal-title":"J Biol Chem"},{"key":"R68-32-20241104","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2133\/dmpk.19.453","article-title":"A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy.","volume":"19","author":"Morimoto","year":"2004","journal-title":"Drug Metab Pharmacokinet"},{"key":"R69-32-20241104","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/tpj.2009.3","article-title":"Functional analysis of a mutation in the SLCO1B1 gene (c.1628TG) identified in a Japanese patient with pravastatin-induced myopathy).","volume":"9","author":"Furihata","year":"2009","journal-title":"Pharmacogenomics J"},{"key":"R70-32-20241104","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.21214","article-title":"Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver.","volume":"44","author":"Meier","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R71-32-20241104","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s10038-002-8653-6","article-title":"Three hundred twenty-six genetic variations in genes encoding nine members of ATP-binding cassette, subfamily B (ABCBMDRTAP), in the Japanese population.","volume":"47","author":"Saito","year":"2002","journal-title":"J Hum Genet"},{"key":"R72-32-20241104","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00008571-200304000-00003","article-title":"Pharmacogenetics of hepatocellular transporters.","volume":"13","author":"Pauli-Magnus","year":"2003","journal-title":"Pharmacogenetics"},{"key":"R73-32-20241104","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/00008571-200308000-00006","article-title":"Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene.","volume":"13","author":"Kroetz","year":"2003","journal-title":"Pharmacogenetics"},{"key":"R74-32-20241104","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","article-title":"Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.","volume":"97","author":"Hoffmeyer","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R75-32-20241104","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/clinchem\/47.6.1048","article-title":"No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients.","volume":"47","author":"von Ahsen","year":"2001","journal-title":"Clin Chem"},{"key":"R76-32-20241104","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1124\/dmd.105.008854","article-title":"Genetic variability, haplotype structures, and ethnic diversity of hepatic transporters MDR3 (ABCB4) and bile salt export pump (ABCB11).","volume":"34","author":"Lang","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"R77-32-20241104","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/00008571-200402000-00003","article-title":"Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy.","volume":"14","author":"Pauli-Magnus","year":"2004","journal-title":"Pharmacogenetics"},{"key":"R78-32-20241104","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1136\/gut.2008.159541","article-title":"Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy.","volume":"58","author":"Dixon","year":"2009","journal-title":"Gut"},{"key":"R79-32-20241104","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3748\/wjg.14.38","article-title":"Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331TC polymorphism in the bile salt export pump.","volume":"14","author":"Meier","year":"2008","journal-title":"World J Gastroenterol"},{"key":"R80-32-20241104","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1053\/j.gastro.2006.11.023","article-title":"Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes.","volume":"132","author":"Daly","year":"2007","journal-title":"Gastroenterology"},{"key":"R81-32-20241104","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/hep.23549","article-title":"A role for the pregnane X receptor in flucloxacillin-induced liver injury.","volume":"51","author":"Andrews","year":"2010","journal-title":"HEPATOLOGY"},{"key":"R82-32-20241104","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1177\/0091270007299930","article-title":"Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs.","volume":"47","author":"Urquhart","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"RU83-32-20241104","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/014860718500900111","article-title":"Does Lonarterm home parenteral nutrition in adult patients cause chronic liver disease?","volume":"9","author":"Bowyer Ba, Fleming","year":"1985","journal-title":"JPEN J Parenterenterl Nutr"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.24229","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201104000-00032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T17:04:23Z","timestamp":1730739863000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201104000-00032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":83,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.24229","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}